CClinicalTrials.gg
CompletedNCT05664659Updated Jul 24, 2023

Efficacy of Carbetocin Versus Oxytocin Plus Misoprostol in Decreasing Blood Loss During Cesarean Section

A Phase 4 interventional study of Oxytocin + misoprostol and Carbetocin in Blood Loss, Surgical and Intrapartum Hemorrhage, sponsored by Ain Shams Maternity Hospital. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-07-24.

Sponsored by Ain Shams Maternity Hospital · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The aim of this clinical trial is to test if carbetocin is as effective as oxytocin plus misoprostol in decreasing intraoperative blood loss in women undergoing planned cesarean section.

The main question it aims to answer is:

* Is carbetocin as effective as oxytocin plus misoprostol in decreasing intraoperative blood loss in women undergoing planned cesarean section?

Researchers will compare 2 groups:

  • women receiving Oxytocin plus Misoprostol;
  • women receiving Carbetocin as regards:
  • estimated blood loss
Read the detailed description
  • Type of Study: A randomized controlled clinical trial.
  • Study Setting: This study will be conducted in Ain Shams University Maternity Hospital (ASUMH).
  • Study duration: 6 months.
  • Study population: Women will be recruited from outpatient antenatal clinic of ASUMH.

Sample Size:

104 patients will be enrolled in this study and will be divided into two groups:

  • Group A: 52 patients will receive+ Oxytocin (20 IU IV infusion on 1000 ml of normal saline solution) plus misoprostol (600 micrograms rectal). ( The control group )
  • Group B: 52 patients will receive 100 micrograms Carbetocin IV slowly. Sample size justification By using PASS 11 software for sample size calculation, setting power at 80%, alpha error at 5% and after reviewing previous study results showed that the haemoglobin level (g/dl) postoperative to caesarean section was higher among women took Carbetocin than those took misoprostol (10.13 ± 0.76 versus 9.57 ± 0.95 respectively); based on that, a sample size of at least 90 pregnant females undergoing elective caesarean section divided randomly into 2 intervention groups [Carbetocin and misoprostol with oxytocin] (45 patients in each group) will be sufficient to achieve study objective, yet the drop out rate 17% so 7 patients will be added in each group.

Procedures:

  1. Approval of the protocol by the ethical committee of the department of Obstetrics \& Gynecology, Faculty of Medicine, Ain Shams University.
  2. Recruitment of patients planning to undergo elective cesarean section in ASUMH from antenatal clinic.
  3. An informed written consent will be taken from all participants before enrollment in the study and after explaining the purpose, possible risks and complications.
  4. All participants will be subjected to thorough history taking, general and abdominal examination, obstetric ultrasound examination and laboratory investigations including complete blood count to identify eligible patients.
  5. The expert consultant will take the decision to do the cesarean section.
  6. Eligible patients will be randomised \& allocated into 2 groups (A) \& (B). Randomization will be done using computer generated list.
  7. Allocation \& concealment will be done using sealed envelopes prepared according to computer generated list into ratio 1:1. Patients will deliver by cesarean section. Patients in group A will receive 600 micrograms misoprostol rectally immediately before sterilization plus 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution immediately after delivery of the fetus.
  8. Patients in group B will receive 100ug Carbetocin by slow IV infusion (over one minute) intra-operative immediately after delivery of the fetus.
  9. Estimation of blood loss will be calculated by :

    • After delivery of the placenta, the amount of blood loss in the suction canister and drapes will be measured.
    • The equation* used when calculating blood loss of a blood-soaked item is WET Item Gram Weight - DRY Item Gram Weight=Milliliters of Blood Within the Item. The items are weighed using a highly accurate digital balance ( Salter digital electronic scale 9037 TL3R).
    • Although a gram is a unit of mass and a milliliter is a unit of volume, the conversion from one to the other is a simple 1-to-1 conversion.
    • The amniotic fluid index (AFI) was estimated using abdominal ultrasound as the sum of the maximum vertical diameter of amniotic fluid in four quadrants in centimeters.
    • Amniotic fluid volume (AFV) (ml) was estimated by multiplying AFI (cm) by 30.
    • At the end of the surgery, the volume of quantified blood calculated by weight will be added to the volume of quantified blood in the suction canister then subtracting the amniotic fluid volume to determine total quantification of blood loss.
  10. Follow up \& data recording; • Post-partum hemorrhage will be considered:
  1. Minor PPH: if estimated blood loss from 500 ml to 1000 ml. 2. Major PPH: if any estimated blood loss is more than 1000 ml.
  • Measuring hemoglobin level before \& after 24 hours of delivery to asses the need for blood transfusion.
  • All data will be recorded in Case Report Form.
02

Conditions studied

  • Blood Loss, Surgical
  • Intrapartum Hemorrhage

Keywords

  • estimated blood loss
  • carbetocin
  • oxytocin
  • misoprostol
03

In context

Hemorrhage

3,000 studies on the registry are indexed under Hemorrhage; 474 are open to participants now.

This study's enrollment of 90 is close to the median of 100 across 1,985 interventional studies indexed under Hemorrhage.

Browse Hemorrhage studies →

Lead sponsor

Ain Shams Maternity Hospital is the lead sponsor of 135 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Pregnant women planning to deliver by CS.
  • Age between 18-40.
  • Gestational age: (36-42 weeks).

Exclusion criteria

Exclusion Criteria:

  1. Women in active labour.
  2. Rupture of membranes more than 24 hours \&/or intraamniotic infection.
  3. Suspected extensive adhesions eg: more than P3CS, endometriosis, previous pelvic surgery.
  4. Antepartum hemorrhage and abnormal placentation e.g.: low lying placenta, placenta previa, placenta accreta.
  5. Major intrapartum hemorrhage more than 1000 ml.
  6. History of postpartum hemorrhage.
  7. Anemia (Hb level less than 10g/dl).
  8. Uterine overdistention eg: polyhydramnios, macrosomic baby, multiple pregnancy.
  9. Known allergy to any of misoprostol, oxytocin, carbetocin.
  10. Known medical disorders: Diabetes Mellitus, hypertensive disorders, Systemic Lupus Erythematosus.
  11. Known coagulopathy problem.
  12. Contraindication \&/or refusal to spinal anesthesia.
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Active comparator
    Oxytocin+Misoprostol

    Patients in this group will receive 600 micrograms misoprostol rectally immediately before sterilization plus 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution immediately after delivery of the fetus.

    Drug: Oxytocin + misoprostol

  • Experimental
    Carbetocin

    Patients in this group will receive 100ug Carbetocin by slow IV infusion (over one minute) intra-operative immediately after delivery of the fetus.

    Drug: Carbetocin

Interventions

  • DrugOxytocin + misoprostol

    600 micrograms misoprostol rectally 20 IU Oxytocin IV infusion on 1000 ml of normal saline solution

  • DrugCarbetocin

    100 micrograms carbetocin

06

What researchers measure

Primary outcomes

  1. estimated blood loss in millimeters

    estimated blood lost during the cesarean section (CS)

    Time frame: calculated once at the end of the CS

Secondary outcomes

  1. drop in hemoglobin

    Difference in Hemoglobin level before and after CS

    Time frame: calculated once after 24hours of the CS

07

Study locations

1 site
  • Ain Shams Maternity Hospital
    Cairo, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — The study protocol and the analytic code will be made available from the central contact on reasonable requests

Supporting information: Study protocol, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05664659
Lead sponsor
Ain Shams Maternity Hospital
Responsible party
Rania Hassan Mostafa (Principal investigator, Ain Shams Maternity Hospital) — Principal investigator
First posted
Dec 27, 2022
Start date
Dec 20, 2022
Primary completion
Apr 30, 2023
Completion
May 20, 2023
Last update
Jul 24, 2023

Study contacts

Mohamed SE Sweed, MD
study director · Ain Shams University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion